NasdaqGM - Delayed Quote USD

Prenetics Global Limited (PRE)

2.9000 -0.2900 (-9.09%)
At close: April 19 at 4:00 PM EDT
2.9300 +0.03 (+1.03%)
After hours: April 19 at 5:30 PM EDT
Loading Chart for PRE
DELL
  • Previous Close 3.1900
  • Open 3.2100
  • Bid 2.8600 x 100
  • Ask 3.0400 x 100
  • Day's Range 2.8500 - 3.2201
  • 52 Week Range 2.8500 - 15.9000
  • Volume 39,514
  • Avg. Volume 80,887
  • Market Cap (intraday) 35.395M
  • Beta (5Y Monthly) -0.11
  • PE Ratio (TTM) 0.67
  • EPS (TTM) 4.3500
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 60.00

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies. In addition, the company, through its equity interests in ACT Genomics Holdings Company Limited, is involved in genomic profiling of solid tumors through ACTOnco. Prenetics Global Limited was founded in 2007 and is based in Quarry Bay, Hong Kong.

www.prenetics.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: PRE

Performance Overview: PRE

Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

PRE
50.93%
S&P 500
4.14%

1-Year Return

PRE
76.93%
S&P 500
19.55%

3-Year Return

PRE
--
S&P 500
14.79%

5-Year Return

PRE
--
S&P 500
14.79%

Compare To: PRE

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: PRE

Valuation Measures

As of 4/18/2024
  • Market Cap

    38.93M

  • Enterprise Value

    -24.65M

  • Trailing P/E

    0.73

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.11

  • Price/Book (mrq)

    0.17

  • Enterprise Value/Revenue

    -0.09

  • Enterprise Value/EBITDA

    2.01

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -288.48%

  • Return on Assets (ttm)

    -10.60%

  • Return on Equity (ttm)

    -24.87%

  • Revenue (ttm)

    21.74M

  • Net Income Avi to Common (ttm)

    -54.35M

  • Diluted EPS (ttm)

    4.3500

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    78.03M

  • Total Debt/Equity (mrq)

    1.13%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: PRE

Analyst Price Targets

60.00
60.00 Average
2.9000 Current
60.00 High
 

Fair Value

Undervalued
% Return
2.9000 Current
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Earnings

Consensus EPS
 

People Also Watch